SS-31

Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.

Binds cardiolipin in the inner mitochondrial membrane; studied for stabilizing electron transport chain integrity.

Mitochondrial stability, oxidative stress reduction, ETC support.

Studied for, research explores, preclinical models suggest, clinical studies have investigated.

Investigated subcutaneously in clinical trials at variable doses across mitochondrial disease research.

Injection site reactions reported in trials; long-term safety data limited.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied for its selective association with cardiolipin on the inner mitochondrial membrane. Research describes interactions that may stabilize cristae architecture, support electron transport chain organization, and modulate reactive oxygen species generated during oxidative phosphorylation.

Within the mitochondrial bioenergetics pathway, SS-31 is positioned upstream of downstream ATP-output endpoints, acting at the membrane-organization layer rather than at substrate input or transcriptional regulation.

• Primary mitochondrial disease research
• Heart failure and cardiac ischemia models
• Age-related skeletal muscle bioenergetics studies
• Renal ischemia-reperfusion preclinical models

Human research exists in mitochondrial disease and cardiac contexts, with mixed clinical outcomes across trials. Preclinical mechanistic data is comparatively stronger than translation to broad clinical endpoints.

Adverse event profiles in clinical trials have generally been described as tolerable for the studied populations. Long-term safety in non-disease populations is not characterized in the public literature.

Most positive findings are disease-specific; generalization to healthy populations is not supported. Trial outcome variability and small sample sizes limit broad conclusions.